CRISPR TherapeuticsCRSP
Market Cap: $3.8B
About: Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.
Employees: 407
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
25% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]
23% more repeat investments, than reductions
Existing positions increased: 155 | Existing positions reduced: 126
7% more call options, than puts
Call options by funds: $127M | Put options by funds: $119M
0.8% less ownership
Funds ownership: 70.89% [Q1] → 70.09% (-0.8%) [Q2]
7% less funds holding
Funds holding: 473 [Q1] → 439 (-34) [Q2]
22% less capital invested
Capital invested by funds: $4.14B [Q1] → $3.21B (-$922M) [Q2]
41% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 83
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
Truist Securities Joon Lee 62% 1-year accuracy 28 / 45 met price target | 124%upside $100 | Buy Maintained | 12 Aug 2024 |
Barclays Gena Wang 42% 1-year accuracy 10 / 24 met price target | 32%upside $59 | Equal-Weight Maintained | 6 Aug 2024 |
RBC Capital Luca Issi 33% 1-year accuracy 16 / 48 met price target | 34%upside $60 | Sector Perform Maintained | 6 Aug 2024 |
Stifel Benjamin Burnett 46% 1-year accuracy 6 / 13 met price target | 32%upside $59 | Hold Maintained | 6 Aug 2024 |
Chardan Capital Geulah Livshits 17% 1-year accuracy 4 / 23 met price target | 111%upside $94 | Buy Maintained | 6 Aug 2024 |
Financial journalist opinion
Based on 7 articles about CRSP published over the past 30 days